Increasing Individual Spending on Healthcare Product is the Reasons that Fuels the Rare Sugar Demand

Manufacturers of rare sugar are witnessing a palpable inclination from food companies eyeing to cater to the needs of customers who are concerned about sugar playing a pivotal role in disease and obesity. Rare sugar is likely to fit in the sugar reduction strategies as millennial and gen Z population show keen interest towards rare sugar.

Commercialization of rare sugar received a major boost following the exemption of allulose from added sugar labelling requirements by FDA in April 2019 which would come into effect from January 2020. Allulose tends to provide a subtle amount of calorie, while still providing the same texture and taste as sucrose.

Allulose has attracted significant attraction in recent years owing to FDA’s GRAS tag given to the ingredient and is subsequently gaining traction in caramel and chocolates as it has an innate ability to brown like sugar and has a crystalline structure.

A notable trend towards the reduction of sucrose has come up as a challenge and an opportunity for rare sugar manufacturers to keep up with the sweet taste of sugar while maintaining the functional upsides of the product.

In the latest research report by Global Market Insights, Inc., rare sugar market size is estimated to surpass US$1.6 billion by 2026.

Rigorous regulations implemented by governing bodies have led food industry to jump on the bandwagon of rare sugar which is low in calorie and label friendly. In fact, D-Mannose has set the trend in dietary supplements to boost urinary tract health (UTI).

In light of humectant upsides, D-Mannose has become one of the major ingredients in cosmetic and personal care end-markets owing to anti-inflammatory, anti-ageing and moisturizing features. It is pertinent to mention that D-Mannose is solvent free, non-GMO and natural, making it highly sought-after in rare sugar industry.

Food industry has exhibited profound interest towards L-Fucose as a naturally occurring sugar manufactured and is prevalently studied as likely anti-cancer and anti-inflammatory agents. Traction for L-Fucose will be more pronounced in pharmaceutical sector and cosmetics as an anti-ageing agent.

L-Fucose with glycans may have a slew of medicinal attributes, such as boosting infant health. Revenue generating opportunities in L-Fucose products will partly emanate from pharmaceuticals, cosmetics and biopharmaceuticals applications.

At the time when consumers are more concerned than ever before towards added sugar and calories, rare sugar market has come up as a viable investment hub for stakeholders, including food companies across the globe.

With the number of people in the U.S. and Canada having diabetes becoming more pronounced, key players in rare sugar market envisage North America as a viable investment hub. So much so that food companies in the U.S. are increasingly investing in sweetener innovation.

According to the CDC report, 44.8% of middle-aged Americans (44 to 59 years) and 40% among young adults aged 20 to 39 years are obese. Accordingly, rare sugar has become a go-to ingredient in dietary supplements in the U.S.

Traction for D-Mannose, L-Fucose and D-Xylose will be apparent in dietary supplements, pharmaceuticals, food and cosmetics. Leading companies will vie to bolster their offerings to cater to the needs of the health-conscious population as food industry and pharmaceuticals sector show inclination towards rare sugar.

Rohini is Business Development Specialist and helping to grow businesses by finding new opportunities and arranging appointments for sales executives. Visit At: https://www.gminsights.com/request-sample/detail/4416